Journal of Health and Rehabilitation Research 2791-156X JHRR
For contributions to JHRR, contact at email: editor@jhrlmc.com

Narrative Review

Insight into Retinal Dystrophy: Understanding Features and Treatment Strategies

Asma Arshad[1]*, Muhammad Aneeq Alyas[2], Sana Arshad[3], Usman Arshad[4]
[1]Department of Zoology, Quaid-i-Azam University, Islamabad, Pakistan
[2]Senior Optometrist, Rabia Eye Clinic, Toba Tek Singh, Pakistan
[3]Aziz Fatimah Medical and Dental College, Faisalabad, Pakistan
[4]Shalamar Medical and Dental College Lahore, Pakistan
Corresponding Author: Asma Arshad; Email: asmaarshad@bs.qau.edu.pk
Conflict of Interest: None.
Arshad A., et al. (2024). 4(2): DOI: https://doi.org/10.61919/jhrr.v4i2.784

ABSTRACT

Retinal dystrophies such as; Retinitis pigmentosa, Congenital Stationary Night Blindness, stargartds disease, lebers congenital amaurosis, and others; present with significant visual impairments due to various genetic mutations affecting retinal function and photoreceptor maintenance. This review explores the diverse landscape of retinal dystrophies, categorizing subtypes based on affected cell types. It sheds light on the clinical characteristics, diagnostic techniques, and complex genetic underpinnings of many illnesses. The study emphasizes the significance of the genetic landscape and enhanced diagnostic tools for prognosis. It also looks at newer forms of treatment, such as gene treatments and pharmaceutical approaches, providing a succinct summary of the developing field. This review, aimed at researchers and clinicians, is a useful tool for comprehending and treating retinal dystrophies.

Keywords: Genetic Disorders, Macular Dystrophy, Retinal Dystrophies, Stargardt Disease, Visual Impairment

1.1 INTRODUCTION

Retinal dystrophies (RDs) are a diverse set of inherited disorders that affect the structure or function of the retina's photoreceptor cells, leading to a progressive and severe loss of vision. With clinical and genetic heterogeneity, retinal dystrophies (RD) are thought to affect as many as 1 in 3000 people. (1, 2). They present with a variety of clinical symptoms.

Peripheral vision problems, color blindness or night blindness, and eventual development to full blindness in progressive diseases are common presentations. Cases might be familial, sporadic, non-syndromic, or both. Inheritance patterns in familial instances may be X-linked, autosomal recessive, or dominant(3). There are also syndromic types in which the trait affects organ systems other than merely retinal degeneration. Unlike non-syndromic cases that exclusively impact the retina, syndromic cases include clinical characteristics that extend to multisystemic involvement.

Defects in the phototransduction and visual cycle pathways, as well as anomalies in the retinal cellular structures, such as the photoreceptors, are the causes of retinal degeneration (RD). The main cellular components that enable phototransduction—the conversion of light energy into a neuronal action potential in the retina and the perception of a picture in the brain—are rod and cone photoreceptors.(4). Rod photoreceptors are responsible for night and peripheral vision whereas cone photoreceptors are responsible for detailed vision and color perception.

Although the precise frequency of retinal dystrophies is unknown, retinitis pigmentosa, the most prevalent kind, affects approximately 1 in 5000 people globally(5). Achromatopsia is one of the rarer dystrophies, having a frequency of 1:30000. RDs have a prevalence of 1:3000 individuals and have a profoundly distressing impact on patients' lives, progressively affecting their mobility and professional functioning.

Depending on the type of photoreceptor impacted and the extent of retinal atrophy, RD can be divided into several general categories. Retinal dystrophies can be further classified as rod-dominated diseases, cone-dominated diseases, or macular dystrophies based on the kind of photoreceptors impacted(6, 7); Fig.1.

Multiple causative gene defects have been identified. Proteins involved in phototransduction, photoreceptors, and other retinal cellular units are encoded by these genes. Even among members of the same family, different diagnoses might result from mutations in the same gene. like cone dystrophy or retinitis pigmentosa. On the other hand, same phenotypes may result from mutations in distinct genes. To date, more than 270 genes associated with retinal dystrophies have been described, but it is believed that there are still many to be identified(8).

For patients with RD, there is presently no treatment or cure—blindness is the only outcome that is certain. New NGS genomic techniques and genome engineering technologies provide revolutionary prospects in enhancing both diagnostic and treatment approaches in the RDs.

This review aims to consolidate current knowledge on the genetic basis, diagnostic tools, and management strategies for CSNB, STGD, and PD, providing a comprehensive resource for ophthalmological practice and genetic counselling.

1.2 METHODOLOGY:

As part of the approach for our review study, we searched a number of databases, including PubMed, MEDLINE, and Google Scholar, for relevant literature. We employed a carefully selected set of search phrases that included pertinent genetic terms and a variety of inherited retinal illnesses, including Retinitis pigmentosa, achromatopsia, congenital stationary night blindness, Stargardt disease, pattern dystrophy, and Leber's congenital amaurosis. Studies were carefully selected for relevance to the genetics, diagnosis, or treatment of these illnesses through an iterative method. For the review's in-depth analysis and synthesis, only the papers that satisfied our inclusion criteria were chosen. Our review paper offered a

Journal of Health and Rehabilitation Research 2791-156X JHRR

thorough and current summary of the genetic factors and clinical issues related to these retinal illnesses because of the methodological approach we used.

1.3 SUBTYPES OF RETINAL DYSTROPHIES

Here; is a summary of each of the subtypes of retinal dystrophies

1.3.1 Cone Dystrophies

Cone-dominated retinal dystrophies are a group of inherited retinal dystrophies that primarily affect the cones in the retina, which is the layer of light-sensitive tissue at the back of the eye. They belong to the group of pigmentary retinopathies affecting 1 in 40,000 individuals. and have a prevalence of 1/40,000(9). Cone photoreceptors comprise 5% of the total photoreceptors in the retina (4.6 million from a total 92 million) with 90% of the cones located in the retinal periphery(10).



Figure 1: Different types of Retinal Dystrophies based on the type of photoreceptor involved

Clinical Presentation

Cone dystrophies present with more severe symptoms compared to rod dystrophies, including heightened light sensitivity, reduced visual clarity, and altered color perception. They typically initiate in childhood, marked by diminished sharpness of vision, followed by compromised central vision, visual field blind spots, and peripheral vision loss. As the condition progresses, individuals may experience night blindness, further loss of peripheral vision, and involuntary eye movements (nystagmus). These symptoms can eventually lead to legal blindness by mid-adulthood, making activities like reading and independent mobility challenging. Later stages result in complete blindness since rod photoreceptors also deteriorate. (11). Both progressive and stationary forms of cone dystrophies may occur. Although less prevalent than retinitis pigmentosa, the condition can be severe due to the loss of high-acuity, color vision preceding night blindness. Fig.2 represents the fundus photograph of a patient with cone-rod dystrophy.

Genetics

Cone-rod dystrophy is mainly inherited through autosomal recessive patterns, involving mutations in both gene copies. Usually, unaffected parents carry one mutated gene each. In fewer instances, it follows an autosomal dominant path, and rarely, it's X-linked recessive. Males are more prone to this condition, while females often experience milder vision issues.

Over 30 genes contribute to cone-rod dystrophy, with roughly 20 linked to the autosomal recessive form. (Retinal dystrophies, genomic applications in diagnosis and prospects for therapy Benjamin M. Nash) ABCA4 mutations are the most prevalent, causing 30-60% of these cases(9, 12). However, numerous causative genes are yet to be discovered, particularly in the autosomal dominant and recessive forms of these disorders.



Fig.2. Fundus of a patient with cone rod dystrophy, different kinds of pigment deposits can be seen and the retina has shrunk.

Treatment

There's currently no cure, but management strategies like corrective lenses, low-vision aids, and lifestyle adjustments can help individuals cope with the condition. Promising avenues like gene therapy and other treatments are under research, holding potential for future interventions to enhance the lives of those with cone dystrophy. Investigations into cone-centered retinal dystrophies concentrate on comprehending disease mechanisms, pinpointing genetic causes, and studying how specific genetic mutations impact retinal function(13).

1.3.1.1 Achromatopsia (ACHM)

Achromatopsia, which largely affects the cone photoreceptors, is an uncommon stationary inherited retinal disorder also referred to as total color blindness or rod monochromacy. About 1 in 30,000 babies are born with achromatopsia, which is usually inherited in an

Journal of Health and Rehabilitation Research 2791-156X JHRR

autosomal recessive fashion(14). As opposed to color blindness, where changes in the genes encoding the different cone photopigments only impact spectrum sensitivity and not the primary function of the photoreceptor (15). ACHM has grave consequences for all aspects of daylight vision mediated by the cone photoreceptors

Signs and Symptoms

Ages ranging from the first year of life to the sixth decade are possible for the beginning of achromatopsia(16). Based on the amount of residual cone function; common symptoms in such patients include; nystagmus, a visual acuity (VA) of 20/200, and variable color blindness. They also exhibit heightened sensitivity to light (photophobia).(14). Refractive errors are also common(17).

Types

It has two subtypes- Complete and incomplete achromatopsia. In ‘complete’ achromatopsia, also known as rod monochromatism all three types of cones (1. Blue, 2. Green, 3. Red) do not function. It is a severe form of achromatopsia where individuals have very poor visual acuity, typically less than 20/200, and complete color blindness(18). They also experience significant photosensitivity and may have pendular nystagmus(19). Alternatively, partial function of one or more cone types may exist in "incomplete" or atypical achromatopsia. It is a less severe version in which people often have superior visual acuity, typically between 20/80 and 20/200, and maintain some color discrimination. Compared to total achromatopsia, their symptoms are less severe, but they still have poor color vision and photosensitivity(8, 20).

Genetics of the disease

Achromatopsia, often caused by mutations in genes like CNGA3(21) and CNGB3(22), disrupts the cyclic nucleotide-gated channel crucial for cone cell function, affecting up to 90% of cases(23).Other genes, including GNAT2(23), PDE6C(24), and PDE6H, and ATF6, also impact cone photoreceptor function(14, 16, 25). These mutations hinder normal signaling in cones, leading to color blindness and reduced visual acuity in bright light. CNGB3 alone contributes to about 50%of complete achromatopsia cases(26). While CNGA3 and CNGB3 mutations predominate, others are rare, collectively accounting for less than 6–8% of cases. Over 100 mutations in CNGA3(14) and nearly 100 in CNGB3(23) have been linked to Achromatopsia in humans. Inheritance is autosomal recessive, with only homozygous or compound heterozygous individuals showing Achromatopsia symptoms, while carriers maintain normal vision.

Diagnosis of the disease

Diagnosing achromatopsia involves a comprehensive approach. In addition to some tests, it depends on clinical observation of signs, symptoms, and family history. A visual acuity and color vision assessment aids in the determination of clarity and color discrimination competencies. A fundus exam may seem normal at first, but in elderly patients, it may reveal macular abnormalities such as vascular attenuations or bull's eye maculopathy. Fig.3; sheds light on the fundus picture of an achromatopsia patient. Whereas Optical Coherence Tomography studies retinal structure, particularly the foveal region, Electroretinography measures cone cell response. Together with genetic analysis, these tests validate the diagnosis, directing treatment and achromatopsia monitoring while providing vital information about retinal health and visual function(8).

Fig. 3 A fundus photograph of a patient with achromatopsia showing blunted foveal reflex and otherwise normal retina.

Management and Prognosis

At the moment, symptom relief rather than going after the disease's underlying cause is the main goal of achromatopsia management(25). Given its inherited foundation, genetic counseling is vital. Investigations into gene therapy, encompassing gene transport, replacement, sequencing, and editing, are currently underway for retinal dystrophies, including achromatopsia(27, 28). Studies on animals have shown that this strategy may be able to restore cone function. The degree of retinal impairment and the age of intervention appear to be related to treatment success (29, 30). Because consanguinity significantly increases the risk of disease, it is crucial to take preventative measures, educate family members, and offer genetic counseling—especially before marriages involving consanguineous relationships or significant family histories.
Using a variety of low-vision aids, such as wrap-around glasses, sunglasses, red-tinted contact lenses, and specialist dark or red-filtered glasses(31). The use of tinted contact lenses in the management of achromatopsia is the primary goal of current achromatopsia treatment efforts. These devices improve visual acuity and successfully lessen photophobia, or sensitivity to light. High-powered magnifiers and electronic devices also help with reading; these are especially helpful for kids with achromatopsia, who should sit in front of the class or away from glare to maximize the effectiveness of their aids(31).

1.3.1.2 Cone Monochromatism:

A congenital condition known as cone monochromatism, which is X-linked recessive in nature, causes color vision deficiencies by either not affecting two of the three cone systems in the retina very well or not at all. Both the red and green cone systems are totally absent in the most prevalent type of monochromatism, known as blue cone. Achromatopsia-like symptoms, such as poor color discrimination and photosensitivity, are common in people with cone monochromatism, who typically have visual acuity between 20/80 and 20/200. They can perceive blue color due to the preservation of the blue cone system(32). Cone monochromatism is diagnosed based on clinical symptoms, color vision testing, and genetic analysis.

1.3.2 ROD DYSTROPHIES

1.3.2.1 Retinitis Pigmentosa (RP)

Retinitis pigmentosa (RP) is the most commonly occurring disease among group inherited retinal disorders known to cause progressive degeneration of the photoreceptor cells in the retina, leading to vision loss and eventual blindness. It is a highly heterogeneous disease with variable onset, progression, and severity, affecting both rod and cone photoreceptors(8). It is the most common inherited retinal dystrophy(IRD) estimated to affect about 1 in 4,000 people; approximately 1.5 million patients worldwide(33, 34, 35). Genetic variation is diverse in retinitis

Journal of Health and Rehabilitation Research 2791-156X JHRR

pigmentosa (RP), including incomplete penetrance, variable expression and penetrance, and heterogeneity in locus and allelic variation. The vast range of clinical symptoms seen in RP patients can be attributed in part to this genetic intricacy(36).

Types

There are two categories for RP: syndromic and non-syndromic. Night blindness is the initial symptom of non-syndromic RP, which progresses to visual loss and finally peripheral vision. Although most cases of RP are not associated with systematic abnormalities, 20-30 % of the patients exhibit extraocular disease(37). Syndromic RP is associated with clinical features that extend to multisystemic involvement beyond just the retina. Usher syndrome is the most common form of syndromic RP, accompanied by loss of hearing followed by bardet biedel syndrome. Others include Senior Loken syndrome, Kearns Sayre Syndrome, Pantothnate kinase associated neuro-degeneration (PKAN)(37). While RP can occur in conjunction with systemic disease, or syndromic RP, the majority of instances have non-syndromic RP, which is characterized by visual loss alone(38). Given that this disease is brought on by mutations in molecular genes, genetic factors are significant. The majority of rod-specific gene mutations that cause RP result in cone degeneration, changes to the retinal pigment epithelium, and ganglion cell abnormalities.

Signs and Symptoms

Retinitis Pigmentosa (RP) frequently begins with vague visual abnormalities that are difficult to detect in the early stages. This is because the substantial genetic diversity linked to RP causes a wide range in the onset and type of symptoms(39, 40). Patients may thus have varying early symptoms and differing times for the disease to manifest. RP is characterized by progressive night blindness, peripheral vision abnormalities, and subsequent progression to tunnel vision and complete blindness. Patients with RP often experience difficulty seeing in low light conditions and may have a gradual loss of peripheral vision, leading to tunnel vision(39).

Midway through, things like driving at night get difficult, severe visual field constriction and legal blindness by age 40(41) are common outcomes of late-stage retinal palsy (RP), with central vision loss by age 60(42). RP can also be associated with other ocular abnormalities, such as cataracts, macular edema, and optic nerve abnormalities(8, 43). This has a significant effect on social relationships, day-to-day functioning, and job performance., RP can lead to the development of characteristic fundus abnormalities, including retinal vessel attenuation, waxy pallor of the optic disc, and bone spicule intraretinal pigmentation.

Genetics of the disease

Due to its genetic variability, inheritance patterns for retinal pigmentosa (RP) might be X-linked, autosomal recessive, autosomal dominant, or digenic. Retinal pigmentation (RP) has been found to be associated with over 100 disease genes. These genes produce proteins involved in phototransduction, tissue growth and maintenance, retinal metabolism, RNA splicing, and cellular architecture.(36, 44). Rhodopsin is produced by the RHO gene, and mutations in this gene are one of the primary causes of autosomal dominant RP. Rhodopsin gene mutations account for 20–30% of autosomal dominant RP cases. Rhodopsin is necessary for phototransduction(45). Autosomal recessive inheritance is associated with mutations in genes relevant to multiple aspects of retinal function, such as PDE6A(44), PDE6B(46), CNGA1, CNGB1(47), and ABCA4(48, 49).

Mutations in the genes CRX(8), NRL(50), and NR2E3(51) which are involved in retinal development and maintenance, are the cause of Retinitis pigmentosa (RP). These genes are critical for rod photoreceptor differentiation during retinal development. Moreover, a specific mutation in the CRX gene has been connected to both cone-rod dystrophy and RP, highlighting the complexity of the genotype-phenotype relationships in both diseases.



Fig.4. Fundus photograph of a patient with Retinitis Pigmentosa.

Diagnosis

RP is diagnosed by looking for specific retinal abnormalities, peripheral vision loss, and night blindness. In addition to peripheral bone spicule deposits, the fundus examination reveals retinal blood vessel loss; Fig.4.

The ERG, which gauges the retina's electrical reaction to a light stimulation, is the gold standard for retinal physiology. The ERG's b-wave is absent or reduced in RP, which suggests that the inner retina—particularly the bipolar cells—isn't functioning properly. This pattern serves as RP's distinguishing feature from other retinal dystrophies(38). An essential measure of the disease's advancement and the effectiveness of treatment is the loss of visual field (VF), which is used to evaluate peripheral vision. It can vary from patchy loss of the peripheral visual region to tunnel vision, ring scotoma, and eventually utter blindness(43, 52). Optical Coherence Tomography (OCT) allows for the visualization of the retinal layers and the determination of the thickness of the photoreceptor layer.

Genes linked to RP, including the RHO gene, can have mutations that can be found by genetic testing. The genetic complexity of RP contributes to the wide range of clinical presentations and challenges in diagnosing illnesses. Even with advances in genetic testing methods, only around 50% of tested patients acquire a molecular diagnosis, highlighting the complexity and genetic heterogeneity of RP(53).

Treatment

There are challenges associated with Retinitis Pigmentosa (RP) because there is no known cure for the condition. Luxturna is the only drug approved for a specific mutation causing RPE65 deficiency, and it targets this genetic defect(41, 54). Complementary vitamin consumption, UV protection, and visual assistance are a few instances of supportive care. Since the generation of 11-cis-vitamin A depends on RPE65, vitamin A supplementation can help manage night blindness by promoting the retinal visual cycle. Nevertheless, there is currently no treatment that may successfully stop or slow the course of RP,

Current studies investigate novel RP treatments such as autologous serum injections. Occupational therapy and vision rehab aid in the management of RP. Neparvovec voretigene only works for a tiny subset of RPE65 mutations, leaving a large unmet need. Although there isn't a permanent cure for RP, therapies including vitamin supplements and visual aids try to slow down its progression. Supplements containing vitamins A and E show promise in treating symptoms. Sunglasses can protect against aggravating circumstances, and devices like magnifying glasses help with night blindness. Because of its intricacy, RP requires constant research to close therapy gaps. Treatment for hereditary Retinitis Pigmentosa (RP) may be possible thanks to research into gene therapy and stem cell technologies. In order to replace damaged cells in the retina, bone marrow-derived stem cell transplantation exhibits potential(55). In clinical trials, people with RP experience encouraging progress when marrow-derived cells are

Journal of Health and Rehabilitation Research 2791-156X JHRR

injected into their vitreous. These developments point to possible near-term developments for gene and cell treatments as a means of treating RP. They present potential opportunities to treat dominantly inherited illnesses such as RP, opening the door to hitherto unthinkable therapeutic approaches. The goals of managing retinitis pigmentosa (RP) are to assist the patient, manage symptoms, and limit the course of the condition.

1.3.2.2 Leber Congenital Amaurosis (LCA)

One of the leading causes of childhood blindness, accounting for 20% of occurrences in this population, is Leber Congenital Amaurosis (LCA)(56, 57). LCA refers to a collection of severe rod-cone dystrophies with early infantile onset that are recessively inherited, first described by Theodore Leber in 1869(58). Mutations in genes essential for the structural or functional maintenance of photoreceptors are the cause of LCA, an early-onset form of retinal degeneration that causes childhood blindness. Globally, LCA affects about 1 in 80,000 children and is thought to be responsible for more than 5% of all inherited retinal diseases (IRD)(59, 60). It may manifest as a stand-alone ocular ailment or as a component of a syndrome, like Senior Loken or Joubert syndrome. Although autosomal dominant inheritance has been reported within some families, autosomal recessive inheritance is the usual mode of inheritance for LCA(61).

Clinical Presentation

People with LCA disease often have severe visual impairments from birth or early childhood. Poor pupillary responses, wandering eyes, and abnormal eye motions are common symptoms(62). Initial eye exams may not reveal any abnormalities, but with time, especially in older people, signs such retinal pigment alterations, optic disc pallor, and retinal clumping may manifest(63); fig.5. One important feature is severe visual impairment; few people are able to see better than 20/400. Nystagmus, photosensitivity, and eye pokes are typical symptoms. Additional systemic disorders such as mental retardation, bone deformities, kidney problems, liver failure, and deafness may be present in more complex instances(63).

Electroretinography (ERG) is frequently used in diagnosis, and it usually reveals very aberrant or undetectable responses. While 20% of people may experience intellectual disability, some people may have normal intelligence. Visual impairments frequently appear before six months of age, making early diagnosis vital as the syndrome can be difficult to distinguish from other inherited retinal disorders(64).

Fig. 5. A fundus photograph of biallelic Leber Congenital Amaurosis showing diffuse retinal pigment epithelial atrophy and vessel attenuation.

Genetics of the disease

Leber Congenital Amaurosis (LCA) is linked to mutations in at least 38 genes(63, 65). i.e; genes i.e GUCY2D (LCA1) RPE65 (LCA2) SPATA7 (LCA3) AIPL1 (LCA4) LCA5 RPGRIP1 (LCA6) CRX (LCA7) RDH12 (LCA13) LRAT (LCA14) TULP1 (LCA15) NMNAT1 (LCA9) CEP290 (LCA10) RPGR (LCA23) IQCB1 (LCA5) LCAKC (LCA11) CRB1 (LCA7) CYP4V2 (LCA3) RD3 (LCA12) SPATA7 (LCA3) RDH12 (LCA13)(62). These genes are mainly active in the eye, particularly in the retina and retinal pigment epithelium.

LCA is a diverse condition, and defects in the CEP290 gene are frequently associated with its progression(66). About 70%–80% of LCA cases are attributed to mutations in GUCY2D, CEP290, CRB1, AIPL1, RDH12, and RPE65(67). They play vital roles in photoreceptor cells. Some patients may also experience kidney issues due to certain genetic variations.

The first gene linked to LCA was GUCY2D, accounting for 10%–20% of cases(68). RPE65-related LCA makes up 5%–10% of cases and has been extensively studied in clinical trials(62, 69).

CRB1 mutations lead to various eye disorders, including early-onset LCA and retinitis pigmentosa. Approximately 10% of LCA patients have CRB1 variants. CEP290-LCA is a prevalent genetic cause, accounting for 15%–20% of cases(61).

Patients with GUCY2D mutations typically have a stable vision, while those with RPE65 mutations may show some improvement followed by a decline. Individuals with other mutations, like AIPL1, CRB1, CEP290, and NMNAT1, usually experience gradual vision loss over several decades. Regular evaluations are recommended, especially for patients with CEP290 or IQCB1 mutations, to check for kidney and neurological issues(60). LCA is usually inherited in a recessive manner, but in rare cases, it can be dominant due to mutations in IMPDH1, OTX2, or CRX genes(59).

Diagnosis

The diagnosis of LCA is clinical; by ophthalmological evaluation and electrophysiology. g and tailored screening of systemic conditions(64).

Most patients show either a normal fundus appearance or subtle RPE changes and retinal vascular attenuation. Keratoconus is seen in 29% of cases. (6)Uncomplicated LCA is diagnosed as bilateral congenital blindness, with a diminished or absent electroretinogram (ERG).

Management of LCA

Management for most patients with LCA typically involves addressing symptoms and providing supportive care. This includes treating potential complications like cataracts, vitreoretinal interphase abnormalities, cystoid macular edema, and keratoconus. Patients are advised to maintain a balanced, healthy diet rich in fruits and vegetables. While vitamin A, mineral, and amino acid supplementation have not shown clear benefits, they are not recommended. UV protection is recommended when outdoors, as UV light can induce oxidative stress in the retina. Environments devoid of nicotine and smoke are recommended because smoking can worsen retinal damage(70, 71). Refractive error correction, the best possible access to employment and educational possibilities, and the use of low vision aids when necessary are all beneficial to patients. A multi-specialist approach is crucial since infants with significant visual impairments may exhibit delays or difficulty in speech, social skills, and behavior(68).

1.3.2.3 Congenital stationary night blindness (CSNB)

Congenital stationary night blindness (CSNB) is a group of non-progressive retinal disorders that have an impact on the transmission of vision signals from photoreceptor cells to bipolar cells inside the retina. Its signs include reduced visual acuity, night vision impairment, and impaired contrast sensitivity. CSNB, which can be inherited in an X-linked, autosomal dominant, or autosomal recessive manner, is associated to mutations in genes pertaining to the visual cycle, neurotransmission, and ion channel activity inside the retina.

Journal of Health and Rehabilitation Research 2791-156X JHRR

Genetics

Congenital stationary night blindness (CSNB) has a complex genetic basis resulting from mutations in multiple genes. The ability of the retina to carry out multiple processes, including neurotransmission, ion channel activity, and the visual cycle, depends on these genes. Currently, 11 genes—CACNA1F, CACNA2D4, TRPM1(72), CABP4, GRM6(73), GNAT1, GRK1, PDE6B, SAG, RHO, and NYX—are linked to CSNB. Glutamate receptor function, calcium binding, calcium channels, and the phototransduction cascade all depend on these genes. One intact alternate route and entire CSNB may emerge from mutations in these genes that disrupt the bipolar cell signaling pathways. Gene mutations involving CACNA1F, CABP4, CACNA2D4, TRPM1, GRM6, GNAT1, PDE6B, RHO, SAG, GRK1, and NYX have been associated with the condition. precise diagnosis, genetic guidance, and potentially targeted treatment.

X-linked complete CSNB (CSNB1) stems from mutations in the NYX gene, disrupting nyctalopin protein in the retina and impairing signaling among retinal cells, particularly bipolar, amacrine, and ganglion cells The cause of X-linked complete CSNB (CSNB1) is mutations in the NYX gene, which affect the retina's nyctalopin protein and the way retinal cells communicate with one another, especially ganglion, bipolar, and amacrine cells (74). The observed CSNB1 phenotype is caused by truncated or non-functioning proteins, albeit the precise signaling mechanism is still unknown.

On the other hand, mutations in the CACNA1F gene cause defective X-linked CSNB (CSNB2), which affects the α1F subunit of calcium channels that connect bipolar cells and rod photoreceptors. These channels become dysfunctional as a result of this disturbance, which lowers calcium ion flow and compromises signaling. Clinically, CSNB2 is seen as a diminished scotopic b-wave on the electrocardiogram (ERG), which suggests impaired communication between these cells(75). Comprehending the genetics of CSNB is essential for precise diagnosis, genetic counseling, and possible focused treatment approaches.

1.3.3 Macular Dystrophy

Macular dystrophies (MDs) are a class of hereditary retinal diseases that mostly result in progressive macular atrophy and cause substantial visual loss. Due to bilateral, rather symmetrical retinal defects, their central visual function is substantially affected. Among the most common subtypes are Sorsby fundus dystrophy (SFD), pattern dystrophy (PD), X-linked retinoschisis (XLRS), Best disease (BD), autosomal dominant drusen (ADD), and Stargardt disease (STGD).

1.3.3.1 Stargardt disease (STGD)

Stargardt disease—also referred to as juvenile macular degeneration or Stargardt's macular dystrophy—affects 10 to 12.5 people per 100,000 in the US and is the most prevalent kind of macular degeneration in children.

A reduction in visual acuity usually occurs in the first or second decade of life for persons with this illness. This is caused by a gradual loss of functional photoreceptors and degeneration of the retinal pigment epithelium (RPE)(76). In Stargardt disease, excessive lipofuscin accumulation results in RPE shrinkage. This in turn triggers the degradation of photoreceptors, especially in the macula, leading to the eventual loss of eyesight. The widespread deposition of lipofuscin in the RPE, which causes retinal flecks to appear fundus-like, is the characteristic characteristic of the condition(77). The disease's clinical features, development rate, degree of retinal involvement, and age at which it initially appears are all very diverse. This range includes significant damage to the rod and cone systems as well as a single instance of macular degeneration(78, 79).

Clinical features

Typically, fundus autofluorescence—a specialized imaging technique—is used to detect stargardt illness, which appears as specks around the center of the eye. The macular region of the retina begins to break down due to the disease's progression, which impairs vision. The degree of reduced central vision varies, but it is a common sign of Stargardt disease. Problems with color vision, sensitivity to light, and a delayed adaptation to darkness are possible symptoms. The disease's severity is influenced by when it first manifests, with earlier onset typically leading to more vision issues(80, 81). Over time, stargardt disease causes a progressive loss of retinal structure and function; however, individual cases and family histories vary greatly, indicating the importance of both heredity and environment(82). Loss of central vision is the primary symptom of the illness; color photography examination of the eye can detect yellow-white specks at the retinal pigment epithelium level and macular atrophy. A variety of retinal appearances can be seen in different Stargardt disease patients, ranging from broad breakdown of the retinal pigment epithelium and choroid to localized atrophy surrounded by flecks(76). Fig.6; shows the fundus appearance of stargardts disease.

Fig,6. Fundus photograph of a patient with Stargardt macular dystrophy demonstrates central macular atrophy with yellow flecks.

Genetics

About 12% of blindness resulting from inherited retinal illnesses is attributed to this prevalent genetic retinal condition(80, 83, 84). Approximately 95% of cases of Stargardt illness are caused by mutations in the ABCA4 gene. This gene produces a transporter that is necessary for the photoreceptor cells in the eye to recycle a material known as 11-cis-retinal. ABCA4 mutations in Stargardt disease cause the synthesis of A2E, a lipofuscin component(84, 85). The retina's photoreceptors and retinal pigment epithelium are both deteriorating due to high lipofuscin levels. The rod and cone cells of the retina are the primary sites of the ABCA4 gene.

Five percent of cases of Stargardt are caused by mutations in other genes, such as PRPH2 and ELOVL4. Mutations in ELOVL4 cause the ELOVL4 protein to aggregate, which impairs cell function and ultimately results in cell death(86).

Diagnosis

When Stargardt disease (STGD1) is first diagnosed, it may not always exhibit normal symptoms during a routine eye exam. Using comprehensive cross-sectional views of the retina and choroid, optical coherence tomography (OCT) is an imaging technique that aids in the visualization of structural changes(87). Techniques include fundus autofluorescence (FAF), spectral-domain optical coherence tomography (SD-OCT), and fluorescein angiography (FA) are frequently used in the diagnosis and characterization of Stargardt illness.

Journal of Health and Rehabilitation Research 2791-156X JHRR

Although scotopic and photopic ERG reductions are rare, electroretinogram (ERG) testing is not routinely performed for Stargardt patients. Sometimes multifocal ERG is used to help detect Stargardt illness early, especially in youngsters. A "beaten-bronze" appearance is typical of Stargardt disease-affected eyes, and occasionally there is also thinning of other retinal layers.

Treatment

There are currently no effective therapies available to reverse Stargardt disease-related vision loss. Low-vision aids are supplied to patients, and they are counseled against taking vitamin A supplements and to avoid excessive sun exposure. To maximize their residual eyesight, assistive technology are offered, and social support is promoted. It is advised to maintain a healthy lifestyle, which includes giving up smoking, in order to decrease the course of disease(78). Sun protection is essential since exposure to bright light can exacerbate visual problems. It's important to avoid taking large amounts of vitamin A in order to stop the illness from getting worse. To control Stargardt illness and optimize visual function, a mix of protective interventions and lifestyle changes is advised.

1.3.3.2 Pattern Dystrophy

A collection of hereditary retinal dystrophies characterized by alterations mostly at the retinal pigment epithelium (RPE) level are collectively referred to as pattern dystrophy (PD). Yellow, orange, or gray pigment deposits in the macula are frequent features associated with mild to severe vision impairment.

The most prevalent inheritance pattern for PDs is autosomal dominant. The most prevalent mutations have been discovered to be in the peripherin/RDS gene (now known as PRPH2)(88). In PDs, the primary defect is presumed to be present in photoreceptor cells, with subsequent damage to RPE and choriocapillaris.

With PHRP2 mutations, variable expressivity is also frequent. Heterozygous mutations might be investigated if a family has one or more of the phenotypes listed above.

Patients frequently show up in their middle years with macular photostress and a central vision impairment. A range of yellow, orange, or gray deposits in the macula may be seen in the fundus. Patients may experience more severe visual loss due to atrophy of the RPE-photoreceptor complex when they present at an elderly age. Pattern dystrophy and age-related macular degeneration (AMD) may be mistaken for one another under certain situations.(89).

1.4 Conclusion

The review identified key genes associated with each condition: CSNB (CACNA1F, NYX, GRM6, etc.), STGD (ABCA4, PRPH2, ELOVL4), and PD (mainly PRPH2). Diagnostic strategies vary, with ERG predominant for CSNB and OCT combined with FAF for STGD and PD. Management is primarily supportive, focusing on maximizing remaining vision and lifestyle adjustments to slow disease progression.

A better knowledge of the pathophysiology of these disorders has been made possible by the identification of the genetic components that contribute to them. Even though developments in gene therapy and other therapeutic modalities provide promise for possible therapies, more study is still desperately needed to fully understand the complex pathways underlying these dystrophies. The analysis also highlights the significance of early diagnosis and individualized patient care strategies. Collaborative efforts between researchers, doctors, and patients will be vital in finding successful therapy methods and improving the overall prognosis for hereditary retinal dystrophies as we continue to unravel their genetic and molecular mysteries.

REFERENCES

1. Bertelsen M, Jensen H, Bregnhøj JF, Rosenberg T. Prevalence of generalized retinal dystrophy in Denmark. Ophthalmic epidemiology. 2014;21(4):217-23.
2. Hamel C. Retinitis pigmentosa. Orphanet journal of rare diseases. 2006;1(1):1-12.
3. Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Human molecular genetics. 2002;11(5):559-68.
4. Chuang J-Z, Hsu Y-C, Sung C-H. Ultrastructural visualization of trans-ciliary rhodopsin cargoes in mammalian rods. Cilia. 2015;4(1):1-15.
5. Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. American journal of ophthalmology. 1984;97(3):357-65.
6. Chawla H, Vohra V. Retinal dystrophies. StatPearls [Internet]: StatPearls Publishing; 2023.
7. Talib M, Boon CJ. Retinal dystrophies and the road to treatment: clinical requirements and considerations. Asia-pacific Journal of Ophthalmology (Philadelphia, Pa). 2020;9(3):159.
8. Nash BM, Wright DC, Grigg JR, Bennetts B, Jamieson RV. Retinal dystrophies, genomic applications in diagnosis and prospects for therapy. Translational pediatrics. 2015;4(2):139.
9. Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis. 2007;2:7.
10. Lamb TD. Why rods and cones? Eye. 2016;30(2):179-85.
11. Thiadens AA, Phan TML, Zekveld-Vroon RC, Leroy BP, van Den Born LI, Hoyng CB, et al. Clinical course, genetic etiology, and visual outcome in cone and cone–rod dystrophy. Ophthalmology. 2012;119(4):819-26.
12. Ducroq D, Rozet J-M, Gerber S, Perrault I, Barbet F, Hanein S, et al. The ABCA4 gene in autosomal recessive cone-rod dystrophies. The American Journal of Human Genetics. 2002;71(6):1480-2.
13. Simunovic MP, Moore AT. The cone dystrophies. Eye. 1998;12(3):553-65.
14. Remmer MH, Rastogi N, Ranka MP, Ceisler EJ. Achromatopsia: a review. Current Opinion in Ophthalmology. 2015;26(5):333-40.
15. Neitz J, Neitz M. The genetics of normal and defective color vision. Vision research. 2011;51(7):633-51.
16. Hirji N, Aboshiha J, Georgiou M, Bainbridge J, Michaelides M. Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic genetics. 2018;39(2):149-57.
17. Poloschek C, Kohl S. Achromatopsia. Der Ophthalmologe. 2010;107:571-82.
18. Michaelides M, Hunt D, Moore A. The cone dysfunction syndromes. The British journal of ophthalmology. 2004;88(2):291.
19. Poloschek CM, Kohl S. [Achromatopsia]. Ophthalmologe. 2010;107(6):571-80; quiz 81-2.
20. Tsang SH, Sharma T. Rod monochromatism (achromatopsia). Atlas of Inherited Retinal Diseases. 2018:119-23.
21. Solaki M, Baumann B, Reuter P, Andreasson S, Audo I, Ayuso C, et al. Comprehensive variant spectrum of the CNGA3 gene in patients affected by achromatopsia. Human mutation. 2022;43(7):832-58.
22. Weisschuh N, Sturm M, Baumann B, Audo I, Ayuso C, Bocquet B, et al. Deep-intronic variants in CNGB3 cause achromatopsia by pseudoexon activation. Human mutation. 2020;41(1):255-64.

Journal of Health and Rehabilitation Research 2791-156X JHRR

23. Felden J, Baumann B, Ali M, Audo I, Ayuso C, Bocquet B, et al. Mutation spectrum and clinical investigation of achromatopsia patients with mutations in the GNAT2 gene. Human Mutation. 2019;40(8):1145-55.
24. Andersen MKG, Bertelsen M, Grønskov K, Kohl S, Kessel L. Genetic and Clinical Characterization of Danish Achromatopsia Patients. Genes. 2023;14(3):690.
25. Danish E, Alhashem A, Aljehani R, Aljawi A, Aldarwish MM, Al Mutairi F, et al. Phenotype and genotype of 15 Saudi patients with achromatopsia: A case series. Saudi Journal of Ophthalmology. 2023;37(4):301-6.
26. Kohl S, Varsanyi B, Antunes GA, Baumann B, Hoyng CB, Jägle H, et al. CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. European Journal of Human Genetics. 2005;13(3):302-8.
27. Ziccardi L, Cordeddu V, Gaddini L, Matteucci A, Parravano M, Malchiodi-Albedi F, et al. Gene therapy in retinal dystrophies. International journal of molecular sciences. 2019;20(22):5722.
28. Broadgate S, Yu J, Downes SM, Halford S. Unravelling the genetics of inherited retinal dystrophies: Past, present and future. Progress in retinal and eye research. 2017;59:53-96.
29. Kohl S, Jägle H, Wissinger B, Zobor D. Achromatopsia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.
30. Remmer MH, Rastogi N, Ranka MP, Ceisler EJ. Achromatopsia: a review. Curr Opin Ophthalmol. 2015;26(5):333-40.
31. Schornack MM, Brown WL, Siemsen DW. The use of tinted contact lenses in the management of achromatopsia. Optometry-Journal of the American Optometric Association. 2007;78(1):17-22.
32. Kellner U, Wissinger B, Tippmann S, Kohl S, Kraus H, Foerster MH. Blue cone monochromatism: clinical findings in patients with mutations in the red/green opsin gene cluster. Graefe's Archive for Clinical and Experimental Ophthalmology. 2004;242:729-35.
33. Birtel J, Gliem M, Mangold E, Müller PL, Holz FG, Neuhaus C, et al. Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa. PloS one. 2018;13(12):e0207958.
34. Orphanet. Prevalence and incidence of rare diseases: Bibliographic data. Inserm; 2021. p. 35.
35. Kocaaga A, Aköz İÖ, Demir NU, Paksoy B. Identification of novel variants in retinitis pigmentosa genes by whole-exome sequencing. Revista da Associação Médica Brasileira. 2023;69:e20221073.
36. Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Archives of ophthalmology. 2007;125(2):151-8.
37. Cortinhal T, Santos C, Vaz-Pereira S, Marta A, Duarte L, Miranda V, et al. Genetic profile of syndromic retinitis pigmentosa in Portugal. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024:1-15.
38. Kamde SP, Anjankar A. Retinitis Pigmentosa: Pathogenesis, Diagnostic Findings, and Treatment. Cureus. 2023;15(10).
39. Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Retinitis pigmentosa: Burden of disease and current unmet needs. Clinical Ophthalmology. 2022:1993-2010.
40. Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Current and future treatment of retinitis pigmentosa. Clinical Ophthalmology. 2022:2909-21.
41. Wu KY, Kulbay M, Toameh D, Xu AQ, Kalevar A, Tran SD. Retinitis Pigmentosa: Novel Therapeutic Targets and Drug Development. Pharmaceutics. 2023;15(2):685.
42. Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Current and Future Treatment of Retinitis Pigmentosa. Clin Ophthalmol. 2022;16:2909-21.
43. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. The Lancet. 2006;368(9549):1795-809.
44. Huang SH, Pittler SJ, Huang X, Oliveira L, Berson EL, Dryja TP. Autosomal recessive retinitis pigmentosa caused by mutations in the α subunit of rod cGMP phosphodiesterase. Nature genetics. 1995;11(4):468-71.
45. Janecke AR, Thompson DA, Utermann G, Becker C, Hübner CA, Schmid E, et al. Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy. Nature genetics. 2004;36(8):850-4.
46. McLaughlin ME, Sandberg MA, Berson EL, Dryja TP. Recessive mutations in the gene encoding the β–subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nature genetics. 1993;4(2):130-4.
47. Bareil C, Hamel C, Delague V, Arnaud B, Demaille J, Claustres M. Segregation of a mutation in CNGB1 encoding the β-subunit of the rod cGMP-gated channel in a family with autosomal recessive retinitis pigmentosa. Human genetics. 2001;108:328-34.
48. Thompson DA, Li Y, McHenry CL, Carlson TJ, Ding X, Sieving PA, et al. Mutations in the gene encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy. Nature genetics. 2001;28(2):123-4.
49. Martínez Mir A, Paloma E, Allikmets R, Ayuso C, Río Td, Dean M, et al. Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease gene ABCR. 1998.
50. Bessant DA, Payne AM, Mitton KP, Wang Q-L, Swain PK, Plant C, et al. A mutation in NRL is associated with autosomal dominant retinitis pigmentosa. Nature genetics. 1999;21(4):355-6.
51. Coppieters F, Leroy BP, Beysen D, Hellemans J, De Bosscher K, Haegeman G, et al. Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. The American Journal of Human Genetics. 2007;81(1):147-57.
52. Muniz A, Villazana-Espinoza ET, Hatch AL, Trevino SG, Allen DM, Tsin AT. A novel cone visual cycle in the cone-dominated retina. Experimental eye research. 2007;85(2):175-84.
53. Neveling K, Collin RW, Gilissen C, Van Huet RA, Visser L, Kwint MP, et al. Next-generation genetic testing for retinitis pigmentosa. Human mutation. 2012;33(6):963-72.
54. Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical perspective: treating RPE65-associated retinal dystrophy. Molecular Therapy. 2021;29(2):442-63.
55. MacLaren RE, Bennett J, Schwartz SD. Gene therapy and stem cell transplantation in retinal disease: the new frontier. Ophthalmology. 2016;123(10):S98-S106.
56. Huang C-H, Yang C-M, Yang C-H, Hou Y-C, Chen T-C. Leber's congenital amaurosis: current concepts of genotype-phenotype correlations. Genes. 2021;12(8):1261.
57. Roy M, Fleisher RC, Alexandrov AI, Horovitz A. Reduced ADP off-rate by the yeast CCT2 double mutation T394P/R510H which causes Leber congenital amaurosis in humans. Communications Biology. 2023;6(1):888.
58. Perrault I, Rozet J-M, Gerber S, Ghazi I, Leowski C, Ducroq D, et al. Leber congenital amaurosis. Molecular genetics and metabolism. 1999;68(2):200-8.
59. Tsang SH, Sharma T. Leber congenital amaurosis. Atlas of inherited retinal diseases. 2018:131-7.
60. Kumaran N, Moore AT, Weleber RG, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. British journal of ophthalmology. 2017.
61. Cremers FP, van den Hurk JA, den Hollander AI. Molecular genetics of Leber congenital amaurosis. Human molecular genetics. 2002;11(10):1169-76.
62. Kumaran N, Moore A, Weleber R. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions (vol 101, pg 1147, 2017). BRITISH JOURNAL OF OPHTHALMOLOGY. 2019;103(6):862-.
63. Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World Journal of Clinical Cases: WJCC. 2015;3(2):112.

Journal of Health and Rehabilitation Research 2791-156X JHRR

64. Pontikos N, Arno G, Jurkute N, Schiff E, Ba-Abbad R, Malka S, et al. Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom. Ophthalmology. 2020;127(10):1384-94.
65. Flanders M, Lapointe M, Brownstein S, Little J. Keratoconus and Leber's congenital amaurosis: a clinicopathological correlation. Canadian Journal of ophthalmology Journal Canadien D'ophtalmologie. 1984;19(7):310-4.
66. McDougald DS, Kmiec E, Mills JA. Personalized models reveal mechanistic and therapeutic insights into CEP290-associated Leber congenital amaurosis. Stem Cell Investigation. 2016;3.
67. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Progress in retinal and eye research. 2008;27(4):391-419.
68. Varela MD, de Guimaraes TAC, Georgiou M, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials. British Journal of Ophthalmology. 2021.
69. Astuti GD, Bertelsen M, Preising MN, Ajmal M, Lorenz B, Faradz SM, et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark. European Journal of Human Genetics. 2016;24(7):1071-9.
70. Hammond Jr BR, Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision research. 1996;36(18):3003-9.
71. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nature Reviews Immunology. 2003;3(11):879-89.
72. van Genderen MM, Bijveld MM, Claassen YB, Florijn RJ, Pearring JN, Meire FM, et al. Mutations in TRPM1 are a common cause of complete congenital stationary night blindness. The American Journal of Human Genetics. 2009;85(5):730-6.
73. Dryja TP, McGee TL, Berson EL, Fishman GA, Sandberg MA, Alexander KR, et al. Night blindness and abnormal cone electroretinogram ON responses in patients with mutations in the GRM6 gene encoding mGluR6. Proceedings of the National Academy of Sciences. 2005;102(13):4884-9.
74. Bech-Hansen NT, Naylor MJ, Maybaum TA, Sparkes RL, Koop B, Birch DG, et al. Mutations in NYX, encoding the leucine-rich proteoglycan nyctalopin, cause X-linked complete congenital stationary night blindness. Nature genetics. 2000;26(3):319-23.
75. Gregg RG, Mukhopadhyay S, Candille SI, Ball SL, Pardue MT, McCall MA, et al. Identification of the gene and the mutation responsible for the mouse nob phenotype. Investigative ophthalmology & visual science. 2003;44(1):378-84.
76. Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefe's Archive for Clinical and Experimental Ophthalmology. 2017;255:1057-62.
77. Binley K, Widdowson P, Loader J, Kelleher M, Iqball S, Ferrige G, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Investigative ophthalmology & visual science. 2013;54(6):4061-71.
78. Mukherjee N, Schuman S, Fekrat S, Scott I. Diagnosis and management of Stargardt disease. Eyenet. 2014:29-31.
79. Heath Jeffery RC, Chen FK. Stargardt disease: Multimodal imaging: A review. Clin Exp Ophthalmol. 2021;49(5):498-515.
80. Fujinami K, Zernant J, Chana RK, Wright GA, Tsunoda K, Ozawa Y, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology. 2015;122(2):326-34.
81. Tanna P, Georgiou M, Aboshiha J, Strauss RW, Kumaran N, Kalitzeos A, et al. Cross-sectional and longitudinal assessment of retinal sensitivity in patients with childhood-onset Stargardt disease. Translational Vision Science & Technology. 2018;7(6):10-.
82. Tanna P, Georgiou M, Strauss RW, Ali N, Kumaran N, Kalitzeos A, et al. Cross-sectional and longitudinal assessment of the ellipsoid zone in childhood-onset Stargardt disease. Translational Vision Science & Technology. 2019;8(2):1-.
83. Heath Jeffery RC, Mukhtar SA, McAllister IL, Morgan WH, Mackey DA, Chen FK. Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia. Ophthalmic Genetics. 2021;42(4):431-9.
84. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Inflammation and retinal disease: complement biology and pathology. 2010:105-25.
85. Quazi F, Lenevich S, Molday RS. ABCA4 is an N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine importer. Nature communications. 2012;3(1):925.
86. Tsang SH, Sharma T. Stargardt disease. Atlas of Inherited Retinal Diseases. 2018:139-51.
87. Heath Jeffery RC, Chen FK. Stargardt disease: Multimodal imaging: A review. Clinical & Experimental Ophthalmology. 2021;49(5):498-515.
88. Pajic B, Weigell-Weber M, Schipper I, KRYENBüHL C, BüCHI ER, Spiegel R, et al. A novel complex mutation event in the peripherin/RDS gene in a family with retinal pattern dystrophy. Retina. 2006;26(8):947-53.
89. Tsai A, Koh A, Wang N-K, Mathur R, Cheung GC. Pattern Dystrophy. Hereditary Chorioretinal Disorders. 2020:75-84.